10,156 Insmed, Inc. $INSM Shares Bought by Chicago Partners Investment Group LLC

Key Points

• Chicago Partners Investment Group increased its Insmed stake by 446.2%, buying 10,156 shares in the third quarter and ending the period with 12,432 shares valued at about $1.16 million.
• Analyst sentiment is broadly positive: Insmed has a consensus “Moderate Buy” rating and an average price target of $196.52, with 24 of 26 analysts rating it Buy or Strong Buy.
• Insmed’s quarterly revenue rose 268.4% year over year to $524.43 million, topping estimates, while its loss per share of $0.46 was wider than analysts’ expected $0.38 loss.

Chicago Partners Investment Group LLC raised its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 446.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,432 shares of the biopharmaceutical company's stock after purchasing an additional 10,156 shares during the quarter. Chicago Partners Investment Group LLC's holdings in Insmed were worth $1,161,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in INSM. Virginia Estate & Retirement Planning Advisors Inc. purchased a new position in shares of Insmed in the third quarter worth about $29,000. SBI Securities Co. Ltd. raised its stake in shares of Insmed by 69.4% during the 3rd quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 143 shares during the period. CX Institutional acquired a new position in Insmed during the third quarter worth $46,000. Harbor Investment Advisory LLC acquired a new position in shares of Insmed during the 2nd quarter worth about $52,000. Finally, Versant Capital Management Inc lifted its position in shares of Insmed by 118.9% in the third quarter. Versant Capital Management Inc now owns 648 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 352 shares in the last quarter.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of recent research reports. Stifel Nicolaus set a $195.00 price target on shares of Insmed in a research report on Thursday, October 29th. The Goldman Sachs Group assumed coverage on Insmed in a research note on Thursday, September 24th. They issued a "buy" rating and a $188.00 price objective for the company. JPMorgan Chase & Co. reduced their target price on shares of Insmed from $179.00 to $175.00 and set an "overweight" rating on the stock in a report on Monday, August 10th. Wells Fargo & Company lifted their price target on shares of Insmed from $161.00 to $169.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Finally, Bank of America reiterated a "buy" rating and set a $207.00 target price on shares of Insmed in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and an average target price of $196.52.

Insmed Stock Performance

INSM opened at $116.10 on Tuesday. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77. The business's 50-day simple moving average is $111.16 and its 200-day simple moving average is $124.16.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The firm's revenue for the quarter was up 268.4% compared to the same quarter last year. During the same period last year, the company earned ($1.75) earnings per share. Analysts forecast that Insmed, Inc. will post -1.86 EPS for the current year.

Insiders Place Their Bets

In related news, Director David Brennan sold 25,000 shares of the company's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director owned 39,238 shares in the company, valued at $4,865,512. This represents a 38.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.10% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr.

Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.